SAB 301

Drug Profile

SAB 301

Alternative Names: SAB-301

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SAB Biotherapeutics
  • Developer National Institutes of Health (USA)
  • Class Antibodies; Antivirals; Monoclonal antibodies; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Middle East respiratory syndrome coronavirus

Most Recent Events

  • 10 Jan 2018 SAB Biotherapeutics completes a phase I trial for Middle East respiratory syndrome coronavirus infection (In volunteers) in USA (IV)
  • 03 Aug 2017 SAB Biotherapeutics plans a phase II trial for Middle East respiratory syndrome coronavirus
  • 24 Aug 2016 SAB Biotherapeutics receives grant from the Biomedical Advanced Research and Development Authority (BARDA) for SAB 301 development in Middle East respiratory syndrome coronavirus infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top